Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: TASMAR

« Back to Dashboard
Tasmar is a drug marketed by Valeant Pharms Llc and is included in one NDA. It is available from one supplier.

The generic ingredient in TASMAR is tolcapone. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tolcapone profile page.

Summary for Tradename: TASMAR

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2

Pharmacology for Tradename: TASMAR

Clinical Trials for: TASMAR

Trial of Tolcapone With Oxaliplatin for Neuroblastoma or Medulloblastoma
Status: Recruiting Condition: Neuroblastoma; Medulloblastoma

Tolcapone Treatment of Pathological Gambling
Status: Completed Condition: Pathological Gambling

Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance
Status: Completed Condition: Healthy

Pilot Study of Tolcapone in Smokers
Status: Completed Condition: Nicotine Dependence

Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With TBI and MCI
Status: Enrolling by invitation Condition: Brain Injuries, Traumatic; Mild Cognitive Impairment

Effects of Tolcapone on Frontotemporal Dementia
Status: Completed Condition: Frontotemporal Lobar Degeneration

Clinical Trial of Tolcapone for Cognition in Schizophrenia
Status: Completed Condition: Schizophrenia

Treatment for Nicotine Addiction in Women
Status: Recruiting Condition: Nicotine Dependence

A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors
Status: Active, not recruiting Condition: Impulsive Behavior

Neural Substrates in Nicotine Withdrawal
Status: Completed Condition: Tobacco Use Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-001Jan 29, 1998RXYes<disabled><disabled>
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-002Jan 29, 1998DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TASMAR

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-001Jan 29, 19985,236,952<disabled>
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-001Jan 29, 19985,476,875<disabled>
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-002Jan 29, 19985,236,952<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc